FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
April 30, 2024 at 13:48 PM EDT
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
